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Serratia marcescens causes health care-associated infections with important morbidity and mortality. Particularly, outbreaks
produced by multidrug-resistant isolates of this species, which is already naturally resistant to several antibiotics, including
colistin, are usually described with high rates of fatal outcomes throughout the world. Thus, it is important to survey factors as-
sociated with increasing frequency and/or emergence of multidrug-resistant S. marcescens nosocomial infections. We report the
investigation and control of an outbreak with 40%mortality due to multidrug-resistant S. marcescens infections that happened
from November 2007 to April 2008 after treatment with colistin for Acinetobacter baumanniimeningitis was started at hospital
H1 in 2005. Since that year, the epidemiological pattern of frequently recovered species has changed, with an increase of S. marc-
escens and Proteus mirabilis infections in 2006 in concordance with a significant decrease of the numbers of P. aeruginosa and A.
baumannii isolates. A single pulsed-field gel electrophoresis (PFGE) cluster of S. marcescens isolates was identified during the
outbreak. When this cluster was compared with S. marcescens strains (n 21) from 10 other hospitals (1997 to 2010), it was also
identified in both sporadic and outbreak isolates circulating in 4 hospitals in Argentina. In132::ISCR1::blaCTX-M-2 was associated
with the multidrug-resistant cluster with epidemic behavior when isolated from outbreaks. Standard infection control interven-
tions interrupted transmission of this cluster even when treatment with colistin continued in several wards of hospital H1 until
now. Optimizing use of colistin should be achieved simultaneously with improved infection control to prevent the emergence of
species naturally resistant to colistin, such as S. marcescens and P. mirabilis.
Serratia marcescens is a Gram-negative, facultative anaerobicbacillus of the Enterobacteriaceae family that survives in envi-
ronments and reservoirs such as drinking water, pipes, and hos-
pital disinfectants as well as in medical instrumentation, among
other locations (1). This organism is able to colonize the human
gastrointestinal tract and skin for extended periods, being trans-
mitted predominantly by person-to-person contact. Pneumonia,
bloodstream infections, meningitis, and ocular and urinary tract
infections can result from an S. marcescens infection (2–6). S.
marcescens is also well known as a nosocomial pathogen and has
been responsible for outbreaks, particularly in critically ill neo-
nates and patients in intensive care units (2, 7–9). Multidrug-
resistant S. marcescens strains are reported to cause more-invasive
infections and tend to spread rapidly in nosocomial environments
(10–13). Recently, several fatal cases associated with nosocomial
infections of this pathogen have been reported around the world
(14, 15). Among other antibiotics, it is naturally resistant to tetra-
cycline, amoxicillin, amoxicillin-clavulanate, cephalothin, and
colistin (16). The latter antibiotic is usually administered as a last-
resort antibiotic for treatment of multidrug-resistant Pseudomo-
nas aeruginosa, Acinetobacter baumannii, and Klebsiella pneu-
moniae infections in Argentina and many other countries (17).
We report the investigation and control of the increasing fre-
quency, including an outbreak, of multidrug-resistant S. marc-
escens infections at hospital H1 in Argentina since the inception of
colistin use in 2005. We have determined the genetic relationship
of S. marcescens isolates of the outbreak, and we compared the
pulsed-field gel electrophoresis (PFGE) profiles with those of ep-
idemiologically well-characterized isolates from outbreaks and
sporadic sources from other 10 hospitals in Argentina (1997 to
2010). The frequencies of other relevant species such as P. aerugi-
nosa, A. baumannii, K. pneumoniae, and Proteus mirabilis col-
lected from hospital H1 during the period 2002 to 2011 were also
statically analyzed. The usage of colistin was revised from the be-
ginning of its administration at hospital H1. In addition, we eval-
uated the presence of complex class 1 integrons and -lactamases
associated with horizontal genetic transfer of S. marcescens iso-
lates.
MATERIALS AND METHODS
Characterization of the institution and epidemiological features of the
outbreak. The study was conducted in a hospital of high complexity with
308 beds, located in the city of Lanús, Province of Buenos Aires, Argentina
(hospital H1). A retrospective analysis of the database of the Microbiology
Laboratory indicated a progressive increase of S. marcescens infections
since 2006 in several wards of hospital H1, with an outbreak by this or-
ganism from November 2007 to April 2008. Consequently, the outbreak
has been studied, including case identification and review of medical re-
cords, environmental cultures, patient surveillance cultures, and person-
nel hand cultures. A total of 50 samples of S. marcescens from 44 patients
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were recovered from November 2007 to April 2008. Thirty-two isolates
were considered to represent infections of this organism, 6 isolates repre-
sented colonization, and the remaining 12 isolates had inadequate data to
determine the infection or colonization source. Among the samples stud-
ied, 54% were from blood and central catheters associated with the use of
vascular access. The remaining isolates were from tracheal aspirates (n
2), bronchoalveolar fluid (n 5), sputum (n 2), pleural liquid (n 3),
urine (n 9), and skin and soft tissue (n 2).
Statistical analysis. Data corresponding to the incidence (by year) of
isolation of S. marcescens and of the most frequent Gram-negative bacilli
collected in hospital H1 (P. aeruginosa,A. baumannii, andK. pneumoniae)
as well as of P. mirabilis, which is also a naturally resistant colistin species,
were statistically evaluated using a two-way analysis of variance and post
hoc least significant difference (LSD) mean comparison analyses.
Bacterial isolates selected formolecular studies. Nine representative
isolates of S. marcescens from the outbreak collected between November
2007 and April 2008 from hospital H1 were selected for molecular studies.
They were compared to other isolates belonging to well-characterized
outbreaks at different hospitals (H2 and H3). Also, 20 sporadic isolates
(from hospitals H1, H2, and H4 to H11) were included in this study
(Table 1). Hospitals H1 to H11 were from 3 provinces of Argentina sep-
arated by more than 250 km (Buenos Aires, Santa Fe, and Entre Ríos).
Isolates were identified at the species level using standard biochemical
tests and by amplified ribosomal DNA restriction analysis for identifica-
tion of Serratia genomic species (24). Until used, isolates were frozen at
80°C in brain heart infusion (BHI) (Difco Laboratories, Detroit, MI)
supplemented with 20% (vol/vol) glycerol.
Antimicrobial susceptibility tests. The disk diffusion method was
performed in agar as recommended by the CLSI (25). Screening methods
for the detection of extended-spectrum -lactamases (ESBLs) and car-
bapenemases were performed both following the guidelines established in
CLSI standards and according to recommendations of the Antimicrobial
Subcommittee of the Sociedad Argentina de Bacteriología, Micología y
Parasitología Clínica (25, 26). The antimicrobial agents included were
ampicillin, cephalothin, amoxicillin-clavulanic acid, cefotaxime, ceftazi-
dime, gentamicin, amikacin, piperacillin-tazobactam, cefepime, nalidixic
acid, ciprofloxacin, trimethoprim and sulfamethoxazole, imipenem, and
meropenem (Oxoid Laboratories, Dartford and Perth, United Kingdom).
PFGE. Genomic DNA embedded in agarose plugs was obtained as
previously described in the PulseNet Standardized Laboratory Protocol
for Escherichia coli O157:H7, Salmonella serotypes, and Shigella sonnei
(27). DNA was digested with XbaI (Fermentas, Lithuania), and digests
were resolved by pulsed-field gel electrophoresis (PFGE) (CHEF-DR III
system; Bio-Rad, Richmond, CA) using electrophoresis conditions of an
initial switch time (IST) of 5 s, a final switch time (FST) of 35 s, and a
running time (RT) of 17 to 18 h at 6 V/cm and 14°C. Salmonella Braen-
derup H9812 was run in multiple positions in each gel (4 lanes in a 15-well
gel) to be used as the standard for the PFGE gels in accordance with
PulseNet International protocols (18). To resolve the PFGE profiles of
some isolates that were recorded as nontypeable, these strains were tested
again with the addition of 50M thiourea to the electrophoresis buffer, as
recommended by other authors (19, 20, 28). PFGE profiles were subjected
to computer-assisted DNA fingerprint analysis using BioNumerics ver-
sion 4.6 software (Applied Maths, Sint-Martens-Latem, Belgium), and
dendrograms were constructed using UPGMA (unweighted-pair group
method using average linkages), the Dice coefficient, and a 1.5% band
position tolerance window. Isolates showing 85% similarities were con-
sidered related.
Identification of genes associated with antibiotic resistance.
Genomic DNA was extracted with a Wizard genomic DNA purification
kit (Promega, Madison, WI). PCR amplifications using total DNA were
performed according to the instructions of the manufacturer (Promega,
Madison, WI) using specific primers for evaluating the presence of anti-
microbial resistance determinants associated with horizontal genetic
transfer and commonly found in Gram-negative bacterial multidrug-re-
sistant clinical isolates from Argentina: (i) integron integrase genes (intI1)
(21), (ii) relevant -lactamase genes (blaCTX-M-2, blaSHV-like, blaPER-2,
blaGES-like, blaVEB-like, blaVIM-like, blaIMP-like, and blaSPM-like) (22), (iii)
qnrB genes (23), and (iv) complex class 1 integrons (21). DNA products
were analyzed by conventional agarose gel electrophoresis and confirmed
by sequencing.
RESULTS
Descriptionof the outbreak inhospitalH1.A retrospective study
indicated a significant increase of S. marcescens infections from
2005 (n 13) to 2007 (n 41) (P 0.0001) (Fig. 1 and Table 2).
Based on the concept of “outbreak,” which is an increase in nos-
ocomial infection rates above that noted in the past, we could
identify an outbreak in the clinical sector from November 2007 to
April 2008 (n  50 isolates). The baseline rate of S. marcescens
infection or colonization in 2005 was 1.0 cases/month, in 2006 the
rate increased to 4 cases/month, and during the outbreak in 2007
to 2008 the rate reached 10 cases/month. During the outbreak
there were 50 cases of infection or colonization caused by S. marc-
escens, with 32 identified as infections; 97% of the 50 cases of
infection or colonization were assisted in the clinical area, suggest-
ing horizontal dissemination from a common source of infection.
The mean age of the patients was 53 years (ranging from 19 to 87
years). Seventeen episodes of infection were found in blood cul-
ture samples possibly associated with previous vascular access.
Fourteen patients died during the outbreak; 13 deaths were attrib-
uted to multidrug-resistant S. marcescens infection (40% of in-
fected patients). It should be noted that no data were available
about the outcome for 22% (7/32) of the infected patients, so it
was not possible to know their evolution, suggesting that the at-
tributable mortality could be greater than 40%.
All the S. marcescens isolates from the outbreak showed the
same multidrug resistance profile, corresponding to resistance to
ampicillin, cephalothin, amoxicillin-clavulanic acid, ceftazidime,
cefotaxime, cefepime, piperacillin-tazobactam, amikacin, genta-
micin, nalidixic acid, ciprofloxacin, trimethoprim, and sulfa-
methoxazole and susceptibility only to imipenem and mero-
penem (Table 1). S. marcescens isolates recovered before and after
the outbreak were susceptible to most of the antibiotics assayed
(Table 1).
Administration of colistin in hospital H1. The use of colistin
began in 2005 with purchase following a request for the treatment
of severe adult postsurgical meningitis due to carbapenem-resis-
tant isolates of A. baumannii. Since 2007 it has been incorporated
in the pharmacotherapy of the hospital as one of the antibiotics of
restricted use for treatment of carbapenem-resistant A. bauman-
nii, P. aeruginosa, or K. pneumoniae infections. The administra-
tion of colistin from 2007 to 2011 has been documented, and it
ranged from 0.5 to 1.5 defined daily doses (DDD).
Analysis of the incidence of infections from 2002 to 2011 in
hospital H1. A two-way analysis of variance with categories of
bacterial species (S. marcescens, P. aeruginosa, A. baumannii, K.
pneumoniae, andP.mirabilis) and year of collection (2002 to 2005,
2006 to 2008, and 2009 to 2011) as factors was conducted (Table 2
and Table 3). The interaction term was statistically significant,
indicating that bacterial species behaved differently through the
years in terms of their frequencies of isolation. In order to detect
the precise source of variation, post hoc LSD tests comparing the
means of the results were conducted (Table 2). These analyses
showed that the incidence of S. marcescens infection or coloniza-
Merkier et al.
2296 jcm.asm.org Journal of Clinical Microbiology
 o
n
 June 20, 2013 by guest
http://jcm.asm.org/
D
ow
nloaded from
 
TABLE 1 Microbiological and molecular features of S. marcescens strains from this study
Hospital/location and
sample no.a
Date of isolate
collection
(mo/day/yr)
Isolate
sourceb
PFGE
subtypec
Gene amplificationd
Antimicrobial sensitivity patterneintI1 blaCTX-M-2 blaPER-2 qnrB
H1/PBA
13007 08/03/2007 TA IX     CAZ, CTX, PTZ, IMP, MER, GEN, AK, NAl, CIP, TMS
13008f 11/13/2007 Bd Ib     IMP, MER
13003f 11/19/2007 Bd Ib     IMP, MER
13006f 12/23/2007 Bd Ib     IMP, MER
13004f 02/25/2008 Bd Ib     IMP, MER
13009f 03/01/2008 Bd Ib     IMP, MER
13010f 04/01/2008 Bd Ib     IMP, MER
13011f 04/07/2008 Bd Ib     IMP, MER
13005f 04/18/2008 Bd Ib     IMP, MER
13001f 04/22/2008 BAL Ib     PTZ, IMP, MER
13015 06/09/2010 BAL NT     CAZ, CTX, PTZ, IMP, MER, GEN, AK, NAl, CIP, TMS
13014 06/30/2010 Bd XIV     CAZ, CTX, PTZ, IMP, MER, GEN, AK, NAl, CIP, TMS
13012 07/19/2010 M-BAL Ib     CAZ, CTX, PTZ, IMP, MER, GEN, AK, NAl, CIP, TMS
13013 07/23/2010 CF X     PTZ, IMP, MER, GEN, AK, NAl, CIP, TMS
H2/SF
886f 2002 CF II     PTZ, IMP, MER, GEN, AK, NAl, CIP, TMS
887f 2002 Bd II     PTZ, IMP, MER, GEN, AK, NAl, CIP, TMS
888f 2002 Bd II     CAZ, CTX, PTZ, IMP, MER, GEN, AK, NAl, CIP, TMS
889f 2002 Bd II     CAZ, CTX, PTZ IMP, MER, GEN, AK, NAl, CIP, TMS
896 2003 Bd V     CAZ, CTX, PTZ, IMP, MER, GEN, AK, NAl, CIP, TMS
H3/PBA
497f 2002 BAL Ic     PTZ, IMP, MER, CIP, GEN, AK, NAL, TMS
H4/BA
15 2001 BAL XIII     CAZ, CTX, PTZ, IMP, MER, GEN, AK, NAl, CIP, TMS
H5/ER
279 2000 Bd VI     PTZ, IMP, MER, CIP, GEN, AK, NAL
H6/PBA
256 1999 Bd VII     PTZ, IMP, MER, CIP, GEN, AK, NAL, TMS
H7/BA
102 1997 BAL III     CAZ, CTX, PTZ, IMP, MER, GEN, AK, NAl, CIP
H8/BA
311 2004 BAL III     PTZ, IMP, MER, NAl, CIP
314 2005 Bd Id     CAZ, CTX, PTZ, IMP, MER, NAl, CIP, GEN
H9/BA
401 2005 Bd XII     CAZ, CTX, PTZ, IMP, MER, GEN, AK, NAl, CIP
404 1998 BAL XI     CAZ, CTX, PTZ, IMP, MER, AK, NAl, CIP, TMS
408 1998 BAL VIII     CTX, PTZ, IMP, MER, AK, NAl, CIP
H10/BA
2000 2006 BAL IV     CAZ, CTX, PTZ, IMP, MER, GEN, AK, NAl, CIP
2001 2006 BAL Ia     PTZ, IMP, MER, AK
H11/BA
1003 2007 BAL Ib     PTZ, IMP, MER, GEN, AK
1002 2008 BAL IV     PTZ, IMP, MER, GEN, AK
1000 2008 BAL Ia     CAZ, CTX, PTZ, IMP, MER, GEN, AK, NAl, CIP, TMS
a PBA, province of Buenos Aires; SF, province of Santa Fé; BA, Buenos Aires City; ER, Province of Entre Ríos.
b TA, tracheal aspirate; Bd, blood; BAL, bronchoalveolar fluid; M-BAL, mini-BAL; CF, cerebrospinal fluid.
c Genotype determined by pulse field gel electrophoresis (PFGE). NT, nontypeable. PFGE patterns were arbitrarily named with a roman number, with letters indicating subtypes
within a cluster (patterns sharing more than 85% similarity [e.g., Ia]) (18–20).
d and, negative and positive, respectively, for gene amplification by PCR by specific primers (21–23).
e All the isolates were resistant for the remaining antibiotic agents. CAZ, ceftazidime; CTX, cefotaxime; PTZ, tazobactam-piperacillin; IMP, imipenem; MER, meropenem; NAL,
nalidixic acid; CIP, ciprofloxacin; GEN, gentamicin; AK, gentamicin; TMS, trimethoprim-sulfamethoxazole.
f Strains isolated during an outbreak.
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tion was significantly higher in the 2006-to-2008 period than in
the other two periods (Fig. 2). This increase was observed after the
treatment of infections caused by carbapenem-resistant A. bau-
manni isolates with colistin which at the same time produced both
a significant decrease of the incidence of P. aeruginosa and A.
baumannii infections from 2005 to the present and a reduction of
the frequency of cases that required the administration of this
antibiotic to date (Fig. 2 and 3 and Table 2). P. mirabilis, also a
naturally colistin-resistant species, showed the same behavior as S.
marcescens; i.e., the incidence of P. mirabilis was significantly
greater in the 2006-to-2008 period (Table 2 and Table 3). During
2002 to 2011, only one other outbreak, due to colistin-resistant
Klebsiella pneumoniae isolates collected in hospital H1 in 2009,
was reported (29).
Microbiological investigation and end of the outbreak. The
retrospective review of S. marcescens infections in the database of
the hospital’s microbiology laboratory was conducted, and an ex-
haustive environmental mapping of patients located in the clinical
medicine area was simultaneously performed. Thirty-three sur-
veillance cultures were done in April 2008 in order to detect pu-
tative nosocomial reservoirs of S. marcescens. Sampling of the en-
vironment (n  13) included hospital stretchers, ventilator
humidifiers, furniture, room surfaces, disinfectant solutions, and
dextrose (5% solution) samples. The staff members (n  20)
(physicians and nurses) were screened for carriage of the organism
by finger impression onto nutrient agar plates. No S. marcescens
isolates were found from surveillance cultures. Although 41% of
the S. marcescens isolates collected from infected patients in No-
vember 2007 and April 2008 were from blood possibly associated
with previous vascular access, no positive cultures were found in
catheters and additional devices. Patients colonized or infected
with multidrug-resistant S. marcescens were kept in isolation
rooms until their discharge in order to minimize cross-transmis-
sion of the microorganism. Notification and education protocols
on S. marcescens and standard infection control procedures were
reviewed together with the hospital personnel. Cleaning, rein-
forcement of hand washing, and disinfection procedures were re-
viewed and strengthened with environmental-service personnel.
The implementation and persistence of these prevention mea-
sures have been effective for the eradication of outbreaks of mul-
tidrug resistant S. marcescens isolates since they were introduced.
Molecular study of S. marcescens isolates from hospital H1
and other hospitals. The 9 isolates from the outbreak at hospital
H1 showed the same PFGE profile and were named cluster I (Fig.
3). These isolates were compared by PFGE to other S. marcescens
isolates belonging to well-characterized outbreak and sporadic
isolates from 10 hospitals in 3 provinces of Argentina (1998 to
2010). Cluster I was highly (more than 85%) related to another
isolate recovered from an outbreak at H3 (isolate 497) and from
sporadic sources (isolates 314, 1000, 2001, and 1003). Strain 13007
isolated before the outbreak in hospital H1, as well as other strains
isolated after the outbreak, presented an unrelated PFGE pattern
(Table 1). The remaining sporadic isolates studied from various
hospitals showed diverse patterns compared to those of cluster I
(Fig. 3 and Table 1).
Antimicrobial resistance determinants of S. marcescens iso-
lates. A different profile of susceptibility was found in strains re-
covered from the outbreak compared to strains isolated before
and after the outbreak in hospital H1. On the one hand, most
isolates that were recovered before and after the outbreak from
infected patients (such as isolates 13007, 13012 13014, and 13015)
were susceptible to most of the antibiotics assayed and belonged to
different clusters (Table 1). On the other hand, all strains corre-
sponding to cluster I isolated from the outbreak’s source in hos-
pitals H1 and H3 were found to carry the blaCTX-M-2 gene which
was found as part of the In132 complex class 1 integron (23). This
class 1 integron possesses the gene cassette aac(6=)-Ib, which con-
fers resistance to amikacin, followed by the gene cassette aadA1,
which confers resistance to streptomycin. Isolate 13011 belonging
to cluster I from hospital H1 and isolated from the outbreak was
also positive for the blaPER-2 gene, and other 4 isolates from the
outbreak, isolates 13001 and 13003 to 13005, were positive for the
qnrB10 gene (Table 1). These genes were also present in the 2001
strain which was a sporadic isolate belonging to cluster I in hospi-
tal H10. Although several isolates harbored the In132::ISCR1::
blaCTX-M-2 complex class 1 integron, which had the aac(6=)-Ib
gene cassette, resistance to amikacin was not detected in some
FIG 1 Isolates of K. pneumoniae, A. baumanni, P. aeruginosa, P. mirabilis, and S. marcescens recovered in 2002 to 2011 in hospital H1.
TABLE 2 Two-way factorial analysis of variance applied to A.
baumannii, K. pneumoniae, P. aeruginosa, P. mirabilis, and S. marcescens
isolates
Parameter
Valuea
SS df MS F P
Intercept 219,711.8 1 219,711.8 2,022.1 0.0001
Species 33,086.8 4 8,271.7 76.1 0.0001
Yrs 201.2 2 100.6 0.9 0.405
Interaction 2,824.2 8 353.0 3.2 0.007
Error 3,803.0 35 108.7
a Data represent square-root-transformed values from comparisons between categories
of years (2002 to 2005, 2006 to 2008, and 2009 to 2011). SS, sum of squares; df, degree
of freedom; MS, mean square; F, analysis of variance (ANOVA) statistics; P, significance
level.
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strains (e.g., 13013, 886, 887, 497, 279, 256, 1002, 1003). This
result is in agreement with previous findings from our laboratory,
since we identified several Gram-negative isolates possessing
aac(6=)-Ib but not exhibiting at a phenotypic level resistance to
amikacin (data not shown).
Transfer of In132::ISCR1::blaCTX-M-2 and In131::ISCR1::
qnrB10 was assayed by biparental conjugation, and it was not pos-
sible to obtain the corresponding transconjugants in either of the
two cases (data not shown). Some of the S. marcescens clusters
corresponding to epidemiologically unrelated isolates were posi-
tive for the blaCTX-M-2 gene, and none of the isolates tested had the
blaSHV-like, blaGES-like, blaVEB-like, blaIMP-like, blaVIM-like, or blaSPM-1
genes.
DISCUSSION
Administration of colistin in several wards of hospital H1 since
2005 was concomitant to (i) a significant increase in the frequency
since 2006 of S. marcescens and P. mirabilis isolates, both species
naturally resistant to that antibiotic, (ii) an outbreak due to the
rapid spread of a multidrug-resistant S.marcescens cluster harbor-
ing complex class 1 integrons with a high rate of mortality (40%)
from November 2007 to April 2008, (iii) a significant decrease of
the incidence of P. aeruginosa and A. baumannii infections since
2005, and (iv) an outbreak due to colistin-resistantK. pneumoniae
from October 2009 to January 2010 (29). These data outline a
scenario in which epidemiological patterns that include infre-
quent species and also multidrug-resistant strains change over the
years due in part to administration of the antibiotic in hospital
settings. The observed correlation between the introduction of
colistin and the increase in the rates of infections by S. marcescens
and P. mirabilis should be confirmed by future studies that inves-
tigate causative relationships.
Cluster I with epidemic behavior of S.marcescenswas dispersed
after 2002 in several cities from Argentina (Table 1). It was iden-
tified in 5 of 11 of the studied hospitals, being in two cases isolated
from outbreaks. This cluster possessed several distinct PFGE sub-
types compared to other clusters, suggesting that it has been evolv-
ing in Argentinean hospital settings for at least a decade (Fig. 1).
Recently, the ability of certain Gram-negative bacilli, including
Enterobacter cloacae and K. pneumoniae, to cause nosocomial out-
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FIG 2 Isolates of the most relevant S. marcescens and Gram-negative bacterial
species isolated from hospital H1 in 2002 to 2011. Each asterisk indicates
statistically significant differences (P 0.05) between the data in the column
with the asterisk above and the data in the one or two columns that are linked
with lines coming out of the asterisk, as determined using the statistical anal-
ysis described in detail in Table 3.
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breaks associated with the spread of epidemic multidrug-resistant
clusters carrying integrons has been documented (30–32). In the
present study, the sporadic isolates of S. marcescens found before
and after the outbreak did not possess class 1 integrons (Table 1).
In contrast, strains from cluster I isolated from outbreaks in hos-
pital H1 and H3 were found to carry the complex class 1 In132::
ISCR1::blaCTX-M-2 integrons. It is likely that this cluster belongs to
this group of Enterobacteriaceae isolates that can be rapidly spread
and maintained in outbreaks due, in part, to the acquisition of
antimicrobial resistance properties conferred by class 1 integrons
and ESBLs. In addition, the finding of blaPER-2 and qnrB10 in
several cluster I strains isolated from the outbreak in hospital H1
supports the idea that accumulation of multiple genetic determi-
nants in a single cell contributes to the evolution of pan-drug-
resistant clusters with epidemic behavior in S. marcescens isolates.
This process can have important clinical and therapeutic implica-
tions, as it is involved in the maintenance and spread of virulent
bacterial cells in the nosocomial environment, increasing nosoco-
mial morbidity and mortality. S. marcescens is a well-recognized
cause of hospital-acquired infection during the three last decades,
mainly in areas of risk and immunocompromised patients. Sev-
eral outbreaks, more commonly in neonatal units than in adults,
have been documented and were associated with a single cluster
(32, 33) as well as with the combination of two or more clusters (3,
34). Here, the mean age of the patients in the clinical area of the H1
hospital was 53 years, a bit higher than what is found in the liter-
ature (32–35). Although an environmental source, mainly hospi-
tal settings and fomites, has been found in some outbreaks (13,
36), most of these events were characterized by the lack of a de-
tectable cause (2, 34). In this study, environmental reservoirs of S.
marcescens in the clinical medicine area were not found, probably
due to the delay in collecting samples after case onset (six months,
from November 2007 to April 2008).
The inception of colistin treatment in hospital H1 and the re-
lated later increase of the recovery of naturally resistant species
such as S. marcescens and P. mirabilis should be taken as signals of
a change in the bacterial epidemiology of the hospital settings.
This resulted not only in already described outbreaks due to selec-
tion of colistin-resistant K. pneumoniae isolates in hospital H1 as
well as in other hospitals (17, 29) but also in a rise in the incidence
of isolation of infrequent species within the nosocomial environ-
ment such as S. marcescens. The success obtained with measures
taken to control the outbreak in hospital H1 showed that it is
necessary to optimize the use of colistin simultaneously with im-
provement of infection control to prevent the spread of species
naturally resistant to colistin in order to preserve this antimicro-
bial agent as a clinical option.
FIG 3 XbaI-PFGE dendrogram of S. marcescens isolates. The cutoff value for cluster delineation was 85% similarity. Isolates included in a cluster (I, II, III, or IV) are
indicated with rectangular boxes. Cluster I included different fingerprints, which were denoted with letters (a, b, c, and d). *, isolates associated with the outbreak.
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